Blood NAD levels are reduced in very old patients hospitalized for heart failure
Introduction
Aging is characterized by a progressive decline in the ability of bioenergetic systems to sustain body needs due notably to systemic metabolic imbalance and mitochondrial dysfunction at the tissue level (Jang et al., 2018). Age-associated decline in nicotinamide adenine dinucleotide (NAD) tissue levels has recently emerged as a potential driving mechanism in the establishment of energy metabolism perturbations in the context of aging and in chronic degenerative diseases (Yaku et al., 2018; Lee et al., 2019). NAD is a major electron carrier coenzyme for all energy substrates oxidation, including glucose, fatty acids and ketone bodies. In its reduced form, NADH coenzyme is the major electron donor to the mitochondrial electron transport chain, providing the energy required to build the proton gradient in the mitochondrial intermembrane space whose driving force is used in turn by the ATP synthase to generate ATP. In its phosphorylated NADP(H) is the major coenzyme for reactive oxygen species (ROS) detoxification systems. In all these processes in which NAD(P) is used as a coenzyme, the total pool of NAD(P), i.e. the sum of oxidized NAD(P)+ and reduced NAD(P)H, is not changed.
However, in its oxidized form, NAD+ is also used as a substrate by a number of signaling pathways that regulate energy metabolism at the transcriptional and enzymatic levels (Sirtuins 1 to 7), the repair of DNA lesions induced by ROS (PARP1) or Ca2+ release from intracellular stores, notably the sarco-endoplasmic reticulum (CD38 ADPribose cyclase) (Mericskay, 2016). All these signaling pathways irreversibly cleave the NAD+ molecule into nicotinamide and ADP-ribose moieties. In physiological condition, the steady-state tissue level of total NAD (sum of NAD+ and NADH) is maintained through compensative NAD biosynthetic pathways. These pathways start with different precursors that include the tryptophane amino acid through the de novo pathway or the vitamins B3, i.e. the nicotinamide, the nicotinic acid and the nicotinamide riboside through three different salvage pathways (Belenky et al., 2007). In the body, the heart is a major energy consuming organ that is able to use all kind of substrates, including glucose, fatty acids and ketone bodies, all of them relying on NAD+ coenzyme to be oxidized. Mitochondrial oxidative metabolism represents the major source of ATP production in the cardiac cells and contains a major fraction of the NAD pool. In heart disease, a severe mitochondrial dysfunction occurs and there is a mismatch between the energy demand and bioenergetic capacities of the myocardium (Zhou and Tian, 2018). In chronic heart failure, the elevated cytosolic concentration of sodium (Na+) in the failing myocytes accelerates Ca2+ efflux via mitochondrial Na+/Ca2+ exchange and consequently, because of the role of Ca2+ in the stimulation of Krebs cycle enzymes and oxidative phosphorylation metabolism, the NADH/NAD+ redox potential decreases (Liu and O'Rourke, 2008). This mismatch between calcium flux perturbations, energy demand and contractility ends up in the generation of high oxidative stress that further contribute to the deterioration of cardiac cell survival and function (Dietl and Maack, 2017). Beyond the alterations in the redox state of the coenzyme, the total pool of NAD can be depressed in upon cardiac injury. Acute ischemic injury was shown to severely depressed myocardial, and notably mitochondrial pool of NAD by 30% through the activation of a NAD glycohydrolase associated to the mitochondrial outer membrane (Lisa et al., 2001). Recently, some studies showed that also, in chronic heart failure, myocardial NAD levels were reduced by 25 to 30% and that restoring NAD levels with NAD precursors supplementation would preserve cardiac NAD levels and cardiac function in preclinical models (Diguet et al., 2018; Vignier et al., 2018; Lee et al., 2016; Horton et al., 2016). We notably identified a new type of metabolic shift for the NAD biosynthetic pathways in the context of dilated cardiomyopathy leading to heart failure, with a repression of the nicotinamide phosphoribosyl transferase (NAMPT), a key enzyme for the recycling of the nicotinamide released by NAD signaling pathways and the activation of the nicotinamide riboside kinase 2 (NMRK2) (Diguet et al., 2018).
Heart failure is also a systemic syndrome presenting complex interactions with other diseases, directly altering the function of numerous peripheric organs such as the kidneys and the liver because of the reduction in blood perfusion and conversely, heart failure prevalence and outcome is modified by the presence of comorbidities such as arterial hypertension, kidney failure, diabetes or obesity. Most of these disease conditions have also been shown to present alterations in tissue NAD levels or redox states (Kane and Sinclair, 2018).
NAD metabolism is not only regulated at the tissue level by the bioenergetic activity of the cells and the rate of NAD consumption by NAD signaling pathways but also at the systemic level by the circulation of NAD and precursors. Blood NAD levels are often measured in clinical studies aiming at evaluating the efficacy of NAD precursors treatment in different condition (Dollerup et al., 2018; Conze et al., 2019; Trammell et al., 2016; Airhart et al., 2017).
Here, we thought to address whether we could detect a change in blood NAD levels: first in a healthy blood donor population following age and sex; second in a population of elderly patients hospitalized for decompensated heart failure, in order to determine whether this type of patients might present an alteration in blood NAD levels and might be in need of NAD precursor supplementation.
Section snippets
Design
This cross-sectional case control study aimed to measure and compare whole blood NAD levels of participants between two populations: elderly patients hospitalized for an decompensated heart failure and voluntary blood donors (VBD) from the French national blood service “Établissement français du Sang” (EFS). This study was conducted from March the 21st to June the 3rd 2016 under the convention #16/EFS/009.
Patients
Elderly patients hospitalized for an unstable heart failure in a geriatric ward of the
Control population
One hundred and fifty-one volunteer blood donors were included in this study: 72 females and 79 males aged from 19 up to 68 years (mean age = 41 years; SD = 15, see Table 1). In this population, the mean concentration of NAD in whole blood samples was 23.4 (SD 4.05) μmol/L; 95% confidence interval of the mean was [22.75–24.05] (Fig. 1A).
The analysis of the donors' age profile suggest that women more often give their blood before the age of 30 and after 56 (Fig. 1B), contrary to men who give it
Discussion
The objective of this study was to assess the NAD blood level in very old patients hospitalized for heart failure and to evaluate the impact of age on this variable in a healthy blood donor control population.
We found a significantly lower NAD blood level in the case group of elderly patients hospitalized for decompensated HF (mean age of 86 years) in comparison to the control population of voluntary blood donors (mean age of 41 years), a priori free from diseases (23.4 vs 20.7 μmol/L; p
Conclusion
This original study explored NAD blood level within a French population of 151 volunteer blood donors aged from 19 up to 68 years and in case population of elderly patients with decompensated heart failure and multiple comorbidities. It highlighted a diminution of NAD blood levels amongst the elderly patients in comparison to the population of volunteer blood donors. With time, research in new therapeutics to restore NAD stock and energy metabolism could be a major progress in the management of
Funding
This study was supported by the “Agence Nationale de la Recherche” ( France) grant NAD-Heart ANR-17-CE17-0015-01 and Fondation de France (France) grant # 00075811.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgments
The authors thank the expert staff of the EFS collection site of Pitié-Salpêtrière and Saint-Antoine/Crozatier, especially Dr. Josiane Taieb, and the clinical team of Charles Foix Hospital (Ivry Sur Seine, “Assistance publique des hôpitaux de Paris”) for their help in collecting patients' consent and collecting and storing blood samples.
CRediT authorship contribution statement
Mathias Mericskay: Conceptualization, Methodology, Supervision. Marie Breton: Investigation, Data curation, Writing - Original draft preparation. Jean-François Costemale-Lacoste: Statistical analyses. Li Zhenlin: Supervision, Reviewing. Carmelo Lafuente: Validation, Reviewing and Editing. Joel Belmin: Clinical Supervision, Reviewing.
References (31)
- et al.
NAD+ metabolism in health and disease
Trends Biochem. Sci.
(2007) - et al.
CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism
Cell Metab.
(2016) - et al.
Whole blood NAD and NADP concentrations are not depressed in subjects with clinical pellagra
J. Nutr.
(2007) - et al.
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects
Am. J. Clin. Nutr.
(2018) - et al.
Surrogate analyte approach for quantitation of endogenous NAD(+) in human acidified blood samples using liquid chromatography coupled with electrospray ionization tandem mass spectrometry
J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci.
(2016) Nicotinamide adenine dinucleotide homeostasis and signalling in heart disease: pathophysiological implications and therapeutic potential
Arch. Cardiovasc. Dis.
(2016)From concept to clinical practice
Exp. Gerontol.
(2017)- et al.
NAD metabolism: implications in aging and longevity
Ageing Res. Rev.
(2018) - et al.
An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers
PLoS One
(2017) - et al.
Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in Wistar rats
PLoS One
(2011)
The plasma NAD+ metabolome is dysregulated in “normal” aging
Rejuvenation Res.
Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults
Sci. Rep.
Targeting mitochondrial calcium handling and reactive oxygen species in heart failure
Curr. Heart Fail. Rep.
Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy
Circulation
Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study
Eur. J. Nutr.
Cited by (15)
Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration
2024, Mechanisms of Ageing and DevelopmentMetabolomics of oxidative stress: Nrf2 independent depletion of NAD or increases of sugar alcohols
2022, Toxicology and Applied PharmacologyCitation Excerpt :Impaired NAD biosynthesis has been found in the tissues from diabetic patients and in animal models of diabetes (Yoshino et al., 2011; Connell et al., 2019; Fan et al., 2020). In addition, depletion of NAD has been observed in patients with heart failure and in animal models of heart failure (Walker and Tian, 2018; Matasic et al., 2018; Breton et al., 2020). While a NAD decrease caused by oxidants has been demonstrated here, whether supplementing NAD can reverse the detrimental effect of oxidative stress remains to be tested.
Advances in Metabolic Remodeling and Intervention Strategies in Heart Failure
2024, Journal of Cardiovascular Translational ResearchRoles of NAD<sup>+</sup> in Health and Aging
2024, Cold Spring Harbor Perspectives in Medicine